

## **Corona / COVID-19 virus situation**

**The situation around the Corona / COVID-19 virus is developing continuously, and Sanofi is rapidly responding to the situation. As a healthcare provider, we are taking necessary steps to prepare ourselves. Both on global and local level taskforces have been established, working on preventive measures to ensure continuation of our operations and the protection of patients, caregivers and our employees and their families.**

**Here you can read more about these actions.**

### **Vaccine development**

Within Sanofi, our global vaccines business unit is leveraging its previous development work on a SARS vaccine as part of our goal to unlock a fast path forward for developing a COVID-19 vaccine. Sanofi is collaborating with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. You can read more about this collaboration [here](#).

Additionally, we are researching whether some on-market products may be a potential treatment option. We are also sharing our expertise in an advisory capacity to various global governments and health agencies, including the World Health Organization (WHO), the U.S. National Institutes of Health (NIH), and the U.S. Centers for Disease Control (CDC).

### **Supply**

Sanofi is working on the continuity of our supply of all our medicines and vaccines through close collaboration with our suppliers throughout the world. At this time, Sanofi does not anticipate shortages for patients resulting from the COVID-19 situation and there has not been any impact on our supply and manufacturing operations.

### **Employee safety**

One of our priorities has been the safety and the health of our employees and their families around the world by implementing science-based recommendations to stop the spread of COVID-19. Sanofi activated its global crisis committee to help prevent employee exposure to the virus while actively monitoring the potential impact on our activities. Local crisis teams in Belgium/the Netherlands are also working to manage local realities in closer proximity to employees.

In line with the guidance from authorities, all our employees are asked to work from home as much as possible. Of course you can continue to reach us if needed via our regular contact details [here](#) .

Sanofi is continually assessing the global health implications of the COVID-19 virus – and our role in addressing this challenge – and we remain committed to working closely with global health organizations and governments to minimize the risk and impact of COVID-19.

**We will continue to monitor the situation and will provide more information if there is any news.**